Pitfalls in the Neuroimaging of Glioblastoma in the Era of Antiangiogenic and Immuno/Targeted Therapy – Detecting Illusive Disease, Defining Response
Tóm tắt
Từ khóa
Tài liệu tham khảo
Stupp, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol, 10, 459, 10.1016/S1470-2045(09)70025-7
Ostrom, 2014, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011, Neuro Oncol, 16, iv1, 10.1093/neuonc/nou223
Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell, 155, 462, 10.1016/j.cell.2013.09.034
Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330
Wen, 2010, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol, 28, 1963, 10.1200/JCO.2009.26.3541
Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, 15, 943, 10.1016/S1470-2045(14)70314-6
Hottinger, 2014, Standards of care and novel approaches in the management of glioblastoma multiforme, Chin J Cancer, 33, 32, 10.5732/cjc.013.10207
Wen, 2014, Report of the jumpstarting brain tumor drug development 5 coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD), Neuro Oncol, 16, vii36, 10.1093/neuonc/nou226
Lamborn, 2008, Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas, Neuro Oncol, 10, 162, 10.1215/15228517-2007-062
Niendorf, 1987, Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors, AJNR Am J Neuroradiol, 8, 803
Macdonald, 1990, Response criteria for phase II studies of supratentorial malignant glioma, J Clin Oncol, 8, 1277, 10.1200/JCO.1990.8.7.1277
Therasse, 2000, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada, J Natl Cancer Inst, 92, 205, 10.1093/jnci/92.3.205
Van den Bent, 2009, End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald’s criteria, J Clin Oncol, 27, 2905, 10.1200/JCO.2009.22.4998
Brandsma, 2008, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas, Lancet Oncol, 9, 453, 10.1016/S1470-2045(08)70125-6
Valtonen, 1997, Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study, Neurosurgery, 41, 44, 10.1097/00006123-199707000-00011
Westphal, 2003, A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma, Neuro Oncol, 5, 79, 10.1215/S1522-8517-02-00023-6
Westphal, 2006, Executive committee of the Gliadel Study Group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial, Acta Neurochir (Wien), 148, 269, 10.1007/s00701-005-0707-z
Brem, 1995, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, Lancet, 345, 1008, 10.1016/S0140-6736(95)90755-6
Subach, 1999, Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series, Neurosurgery, 45, 17, 10.1097/00006123-199907000-00004
Della Puppa, 2010, The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series, Acta Neurochir (Wien), 152, 1923, 10.1007/s00701-010-0759-6
Ulmer, 2012, Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma, Neuro Oncol, 14, 482, 10.1093/neuonc/nos003
Colen, 2011, Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study, World J Radiol, 3, 266, 10.4329/wjr.v3.i11.266
Rosen, 1990, Perfusion imaging with NMR contrast agents, Magn Reson Med, 14, 249, 10.1002/mrm.1910140211
Villringer, 1988, Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects, Magn Reson Med, 6, 164, 10.1002/mrm.1910060205
Rosen, 1991, Contrast agents and cerebral hemodynamics, Magn Reson Med, 19, 285, 10.1002/mrm.1910190216
Emblem, 2009, An automatic procedure for normalization of cerebral blood volume maps in dynamic susceptibility contrast-based glioma imaging, AJNR Am J Neuroradiol, 30, 1929, 10.3174/ajnr.A1680
Bedekar, 2010, Standardization of relative cerebral blood volume (rCBV) image maps for ease of both inter- and intrapatient comparisons, Magn Reson Med, 64, 907, 10.1002/mrm.22445
Jain, 2007, First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis, Neurosurgery, 61, 778, 10.1227/01.NEU.0000298906.48388.26
Barajas, 2009, Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging, Radiology, 253, 486, 10.1148/radiol.2532090007
Hu, 2009, Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements, AJNR Am J Neuroradiol, 30, 552, 10.3174/ajnr.A1377
Matsusue, 2010, Distinction between glioma progression and post-radiation change by combined physiologic MR imaging, Neuroradiology, 52, 297, 10.1007/s00234-009-0613-9
Sugahara, 2000, Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue, AJNR Am J Neuroradiol, 21, 901
Baek, 2012, Percent change of perfusion skewness and kurtosis: a potential imaging biomarker for early treatment response in patients with newly diagnosed glioblastomas, Radiology, 264, 834, 10.1148/radiol.12112120
Hu, 2012, Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival, Neuro Oncol, 14, 919, 10.1093/neuonc/nos112
Tsien, 2010, Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma, J Clin Oncol, 28, 2293, 10.1200/JCO.2009.25.3971
Cao, 2006, Estimate of vascular permeability and cerebral blood volume using Gd-DTPA contrast enhancement and dynamic T2*-weighted MRI, J Magn Reson Imaging, 24, 288, 10.1002/jmri.20634
Mangla, 2010, Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma, Radiology, 256, 575, 10.1148/radiol.10091440
Paulson, 2008, Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors, Radiology, 249, 601, 10.1148/radiol.2492071659
Hu, 2010, Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas, AJNR Am J Neuroradiol, 31, 40, 10.3174/ajnr.A1787
Uematsu, 2006, Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability, Eur Radiol, 16, 180, 10.1007/s00330-005-2807-9
Boxerman, 2006, Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not, AJNR Am J Neuroradiol, 27, 859
Kassner, 2000, Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity, J Magn Reson Imaging, 11, 103, 10.1002/(SICI)1522-2586(200002)11:2103::AID-JMRI53.0.CO;2-Z
Bjornerud, 2011, T1- and T2*-dominant extravasation correction in DSC-MRI: part I – theoretical considerations and implications for assessment of tumor hemodynamic properties, J Cereb Blood Flow Metab, 31, 2041, 10.1038/jcbfm.2011.52
Emblem, 2011, (1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients, J Cereb Blood Flow Metab, 31, 2054, 10.1038/jcbfm.2011.39
Gahramanov, 2013, Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival, Radiology, 266, 842, 10.1148/radiol.12111472
Tofts, 1991, Measurement of the blood–brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts, Magn Reson Med, 17, 357, 10.1002/mrm.1910170208
Tofts, 1997, Modeling tracer kinetics in dynamic Gd-DTPA MR imaging, J Magn Reson Imaging, 7, 91, 10.1002/jmri.1880070113
Tofts, 1999, Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols, J Magn Reson Imaging, 10, 223, 10.1002/(SICI)1522-2586(199909)10:3223::AID-JMRI23.0.CO;2-S
Larsen, 2013, Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis, Neuroradiology, 55, 361, 10.1007/s00234-012-1127-4
Bisdas, 2011, Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging, Acad Radiol, 18, 575, 10.1016/j.acra.2011.01.018
Narang, 2011, Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion, Neuro Oncol, 13, 1037, 10.1093/neuonc/nor075
Kim, 2014, Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility, Radiology, 273, 831, 10.1148/radiol.14132868
Williams, 1992, Magnetic resonance imaging of perfusion using spin inversion of arterial water, Proc Natl Acad Sci U S A, 89, 212, 10.1073/pnas.89.1.212
Silva, 2000, Imaging blood flow in brain tumors using arterial spin labeling, Magn Reson Med, 44, 169, 10.1002/1522-2594(200008)44:2169::AID-MRM13.0.CO;2-U
Furtner, 2014, Arterial spin-labeling assessment of normalized vascular intratumoral signal intensity as a predictor of histologic grade of astrocytic neoplasms, AJNR Am J Neuroradiol, 35, 482, 10.3174/ajnr.A3705
Warmuth, 2003, Quantification of blood flow in brain tumors: comparison of arterial spin labeling and dynamic susceptibility-weighted contrast-enhanced MR imaging, Radiology, 228, 523, 10.1148/radiol.2282020409
Choi, 2013, Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging, Acta Radiol, 54, 448, 10.1177/0284185112474916
Geer, 2012, Does MR perfusion imaging impact management decisions for patients with brain tumors? A prospective study, AJNR Am J Neuroradiol, 33, 556, 10.3174/ajnr.A2811
Yamasaki, 2005, Apparent diffusion coefficient of human brain tumors at MR imaging1, Radiology, 235, 985, 10.1148/radiol.2353031338
Guo, 2002, Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics1, Radiology, 224, 177, 10.1148/radiol.2241010637
Dorenbeck, 2005, Diffusion-weighted imaging with calculated apparent diffusion coefficient of enhancing extra-axial masses, J Neuroimaging, 15, 341, 10.1177/1051228405279991
Rumboldt, 2006, Apparent diffusion coefficients for differentiation of cerebellar tumors in children, AJNR Am J Neuroradiol, 27, 1362
Hayashida, 2006, Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity, AJNR Am J Neuroradiol, 27, 1419
Sugahara, 1999, Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas, J Magn Reson Imaging, 9, 53, 10.1002/(SICI)1522-2586(199901)9:153::AID-JMRI73.0.CO;2-2
Murakami, 2009, Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method1, Radiology, 251, 838, 10.1148/radiol.2513080899
Higano, 2006, Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis1, Radiology, 241, 839, 10.1148/radiol.2413051276
Kitis, 2005, Minimum apparent diffusion coefficients in the evaluation of brain tumors, Eur J Radiol, 55, 393, 10.1016/j.ejrad.2005.02.004
Ellingson, 2010, Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity, J Magn Reson Imaging, 31, 538, 10.1002/jmri.22068
Provenzale, 2004, Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging1, Radiology, 232, 451, 10.1148/radiol.2322030959
Smith, 2005, Serial diffusion-weighted magnetic resonance imaging in cases of glioma: distinguishing tumor recurrence from postresection injury, J Neurosurg, 103, 428, 10.3171/jns.2005.103.3.0428
Hein, 2004, Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury, AJNR Am J Neuroradiol, 25, 201
Asao, 2005, Diffusion-weighted imaging of radiation-induced brain injury for differentiation from tumor recurrence, AJNR Am J Neuroradiol, 26, 1455
Sundgren, 2006, Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions, Magn Reson Imaging, 24, 1131, 10.1016/j.mri.2006.07.008
Chenevert, 2000, Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors, J Natl Cancer Inst, 92, 2029, 10.1093/jnci/92.24.2029
Chenevert, 1997, Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging, Clin Cancer Res, 3, 1457
Ellingson, 2013, Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy, Neuro Oncol, 15, 382, 10.1093/neuonc/nos314
Ellingson, 2012, Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma, Neuro Oncol, 14, 333, 10.1093/neuonc/nor220
Oz, 2014, Clinical proton MR spectroscopy in central nervous system disorders, Radiology, 270, 658, 10.1148/radiol.13130531
Schlemmer, 2001, Proton MR spectroscopic evaluation of suspicious brain lesions after stereotactic radiotherapy, AJNR Am J Neuroradiol, 22, 1316
Dowling, 2001, Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens, AJNR Am J Neuroradiol, 22, 604
Rabinov, 2002, In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience, Radiology, 225, 871, 10.1148/radiol.2253010997
Prat, 2010, Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas, J Clin Neurosci, 17, 50, 10.1016/j.jocn.2009.02.035
McKnight, 2002, Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence, J Neurosurg, 97, 794, 10.3171/jns.2002.97.4.0794
Yang, 2010, Distinguishing glioma recurrence from treatment effect after radiochemotherapy and immunotherapy, Neurosurg Clin N Am, 21, 181, 10.1016/j.nec.2009.08.003
Rock, 2004, Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis, Neurosurgery, 54, 1111, 10.1227/01.NEU.0000119328.56431.A7
Weybright, 2005, Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy, AJR Am J Roentgenol, 185, 1471, 10.2214/AJR.04.0933
Zeng, 2007, Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury, J Neurooncol, 84, 63, 10.1007/s11060-007-9341-3
Smith, 2009, Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions, AJR Am J Roentgenol, 192, W45, 10.2214/AJR.07.3934
Zhang, 2014, Role of magnetic resonance spectroscopy for the differentiation of recurrent glioma from radiation necrosis: a systematic review and meta-analysis, Eur J Radiol, 83, 2181, 10.1016/j.ejrad.2014.09.018
Estève, 1998, Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy, Int J Radiat Oncol Biol Phys, 40, 279, 10.1016/S0360-3016(97)00714-1
Kaminaga, 2005, Radiation-induced brain metabolic changes in the acute and early delayed phase detected with quantitative proton magnetic resonance spectroscopy, J Comput Assist Tomogr, 29, 293, 10.1097/01.rct.0000161422.95625.8a
Di Chiro, 1982, Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography, Neurology, 32, 1323, 10.1212/WNL.32.12.1323
Kincaid, 1998, Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT, AJNR Am J Neuroradiol, 19, 801
Delbeke, 1995, Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET, Radiology, 195, 47, 10.1148/radiology.195.1.7892494
Di Chiro, 1987, Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool, Invest Radiol, 22, 360, 10.1097/00004424-198705000-00002
Hustinx, 1999, Can the standardized uptake value characterize primary brain tumors on FDG-PET?, Eur J Nucl Med, 26, 1501, 10.1007/s002590050487
Kosaka, 2008, 18F-FDG PET of common enhancing malignant brain tumors, AJR Am J Roentgenol, 190, W365, 10.2214/AJR.07.2660
De Witte, 2000, FDG-PET as a prognostic factor in high-grade astrocytoma, J Neurooncol, 49, 157, 10.1023/A:1026518002800
Pardo, 2004, Correlation of FDG-PET interpretation with survival in a cohort of glioma patients, Anticancer Res, 24, 2359
Tralins, 2002, Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation, J Nucl Med, 43, 1667
Spence, 2002, 2-[(18)F]Fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome, Clin Cancer Res, 8, 971
Kelloff, 2005, Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development, Clin Cancer Res, 11, 2785, 10.1158/1078-0432.CCR-04-2626
Kim, 2010, Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI, Clin Neurol Neurosurg, 112, 758, 10.1016/j.clineuro.2010.06.005
Gómez-RÃo, 2008, Diagnostic accuracy of 201Thallium-SPECT and 18F-FDG-PET in the clinical assessment of glioma recurrence, Eur J Nucl Med Mol Imaging, 35, 966, 10.1007/s00259-007-0661-5
Ricci, 1998, Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography?, AJNR Am J Neuroradiol, 19, 407
Di Chiro, 1988, Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies, AJR Am J Roentgenol, 150, 189, 10.2214/ajr.150.1.189
Valk, 1988, PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome, J Neurosurg, 69, 830, 10.3171/jns.1988.69.6.0830
Spence, 2004, 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter, J Nucl Med, 45, 1653
Horky, 2011, Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis, J Neurooncol, 103, 137, 10.1007/s11060-010-0365-8
Padma, 2003, Prediction of pathology and survival by FDG PET in gliomas, J Neurooncol, 64, 227, 10.1023/A:1025665820001
Kubota, 1992, Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography, J Nucl Med, 33, 1972
Isselbacher, 1972, Sugar and amino acid transport by cells in culture – differences between normal and malignant cells, N Engl J Med, 286, 929, 10.1056/NEJM197204272861707
Busch, 1959, The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues, Cancer Res, 19, 1030
Kato, 2008, Analysis of 11C-methionine uptake in low-grade gliomas and correlation with proliferative activity, AJNR Am J Neuroradiol, 29, 1867, 10.3174/ajnr.A1242
Sato, 1999, Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining, Neurosurg Rev, 22, 210, 10.1007/s101430050018
Bergström, 1983, Discrepancies in brain tumor extent as shown by computed tomography and positron emission tomography using [68Ga]EDTA, [11C]glucose, and [11C]methionine, J Comput Assist Tomogr, 7, 1062, 10.1097/00004728-198312000-00022
Ericson, 1985, Positron emission tomography with ([11C]methyl)-l-methionine, [11C] d-glucose, and [68Ga]EDTA in supratentorial tumors, J Comput Assist Tomogr, 9, 683, 10.1097/00004728-198507010-00005
Lilja, 1985, Dynamic study of supratentorial gliomas with l-methyl-11C-methionine and positron emission tomography, AJNR Am J Neuroradiol, 6, 505
De Witte, 2001, Positron emission tomography with injection of methionine as a prognostic factor in glioma, J Neurosurg, 95, 746, 10.3171/jns.2001.95.5.0746
Li, 2012, 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas, Chin Med J (Engl), 125, 91
Van Laere, 2005, Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value, Eur J Nucl Med Mol Imaging, 32, 39, 10.1007/s00259-004-1564-3
Chung, 2002, Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET, Eur J Nucl Med Mol Imaging, 29, 176, 10.1007/s00259-001-0690-4
Go, 1994, Contribution of magnetic resonance spectroscopic imaging and l-[1-11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy, Neurosurgery, 34, 994, 10.1227/00006123-199406000-00007
Willemsen, 1995, In vivo protein synthesis rate determination in primary or recurrent brain tumors using l-[1-11C]-tyrosine and PET, J Nucl Med, 36, 411
Heesters, 1998, 11C-tyrosine position emission tomography and 1H magnetic resonance spectroscopy of the response of brain gliomas to radiotherapy, Neuroradiology, 40, 103, 10.1007/s002340050548
Ullrich, 2008, Glioma proliferation as assessed by 3’-fluoro-3’-deoxy-l-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma, Clin Cancer Res, 14, 2049, 10.1158/1078-0432.CCR-07-1553
Schiepers, 2010, Kinetics of 3’-deoxy-3’-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma, J Nucl Med, 51, 720, 10.2967/jnumed.109.068361
Muzi, 2006, Kinetic analysis of 3’-deoxy-3’-18F-fluorothymidine in patients with gliomas, J Nucl Med, 47, 1612
Spence, 2009, NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3’-deoxy-3’-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies, Mol Imaging Biol, 11, 343, 10.1007/s11307-009-0215-2
Pöpperl, 2004, Value of O-(2-[18F]fluoroethyl)-l-tyrosine PET for the diagnosis of recurrent glioma, Eur J Nucl Med Mol Imaging, 31, 1464, 10.1007/s00259-004-1590-1
Pauleit, 2005, O-(2-[18F]fluoroethyl)-l-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas, Brain, 128, 678, 10.1093/brain/awh399
Rachinger, 2005, Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas, Neurosurgery, 57, 505, 10.1227/01.NEU.0000171642.49553.B0
Dunet, 2012, Performance of 18F-fluoro-ethyl-tyrosine (18F-FET) PET for the differential diagnosis of primary brain tumor: a systematic review and Metaanalysis, J Nucl Med, 53, 207, 10.2967/jnumed.111.096859
Weber, 2000, O-(2-[18F]fluoroethyl)-l-tyrosine and l-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study, Eur J Nucl Med, 27, 542, 10.1007/s002590050541
Heiss, 1996, F-Dopa as an amino acid tracer to detect brain tumors, J Nucl Med, 37, 1180
Becherer, 2003, Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine, Eur J Nucl Med Mol Imaging, 30, 1561, 10.1007/s00259-003-1259-1
Schiepers, 2007, 18F-FDOPA kinetics in brain tumors, J Nucl Med, 48, 1651, 10.2967/jnumed.106.039321
Fueger, 2010, Correlation of 6-18F-fluoro-l-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas, J Nucl Med, 51, 1532, 10.2967/jnumed.110.078592
Ledezma, 2009, 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience, Eur J Radiol, 71, 242, 10.1016/j.ejrad.2008.04.018
Chen, 2006, 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy, J Nucl Med, 47, 904
Oborski, 2014, Assessment of early therapy response with 18F-FLT PET in glioblastoma multiforme, Clin Nucl Med, 39, e431, 10.1097/RLU.0000000000000321
Galldiks, 2012, Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-l-tyrosine PET in comparison to MRI, J Nucl Med, 53, 1048, 10.2967/jnumed.111.098590
Piroth, 2011, Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme, Int J Radiat Oncol Biol Phys, 80, 176, 10.1016/j.ijrobp.2010.01.055
Batchelor, 2010, Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma, J Clin Oncol, 28, 2817, 10.1200/JCO.2009.26.3988
Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021
Norden, 2009, An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma, J Neurooncol, 92, 149, 10.1007/s11060-008-9745-8
Melhem, 1999, Dynamic T1-weighted spin-echo MR imaging: the role of digital subtraction in the demonstration of enhancing brain lesions, J Magn Reson Imaging, 9, 503, 10.1002/(SICI)1522-2586(199904)9:4503::AID-JMRI13.0.CO;2-0
Kanaly, 2011, A novel method for volumetric MRI response assessment of enhancing brain tumors, PLoS One, 6, e16031, 10.1371/journal.pone.0016031
Ellingson, 2014, Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial, Radiology, 271, 200, 10.1148/radiol.13131305
Ellingson, 2012, Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab, J Neurooncol, 106, 111, 10.1007/s11060-011-0638-x
Hattingen, 2013, Quantitative T2 mapping of recurrent glioblastoma under bevacizumab improves monitoring for non-enhancing tumor progression and predicts overall survival, Neuro Oncol, 15, 1395, 10.1093/neuonc/not105
Jalali, 2014, MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy, Neuro Oncol, 16, 868, 10.1093/neuonc/nou040
Pope, 2009, Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment, Radiology, 252, 182, 10.1148/radiol.2521081534
Pope, 2012, Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study, J Neurooncol, 108, 491, 10.1007/s11060-012-0847-y
Rahman, 2014, Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab, J Neurooncol, 119, 149, 10.1007/s11060-014-1464-8
Nowosielski, 2011, ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma, Neuroradiology, 53, 291, 10.1007/s00234-010-0808-0
Ellingson, 2011, Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab, Neuro Oncol, 13, 1151, 10.1093/neuonc/nor079
Ellingson, 2011, Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI, Magn Reson Med, 65, 1131, 10.1002/mrm.22688
Gerstner, 2010, Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib, Neuro Oncol, 12, 466, 10.1093/neuonc/nop051
Jain, 2010, Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker, J Neurooncol, 96, 423, 10.1007/s11060-009-9981-6
Seo, 2008, High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2, AJNR Am J Neuroradiol, 29, 458, 10.3174/ajnr.A0842
Kang, 2011, Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging – correlation with tumor grade, Radiology, 261, 882, 10.1148/radiol.11110686
Yamasaki, 2012, Advantages of high b-value diffusion-weighted imaging to diagnose pseudo-responses in patients with recurrent glioma after bevacizumab treatment, Eur J Radiol, 81, 2805, 10.1016/j.ejrad.2011.10.018
Sorensen, 2009, A “vascular normalization index†as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients, Cancer Res, 69, 5296, 10.1158/0008-5472.CAN-09-0814
Batchelor, 2013, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation, Proc Natl Acad Sci U S A, 110, 19059, 10.1073/pnas.1318022110
Jain, 2005, Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819
Essock-Burns, 2011, Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma, Neuro Oncol, 13, 119, 10.1093/neuonc/noq143
Jain, 2011, In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas, AJNR Am J Neuroradiol, 32, 388, 10.3174/ajnr.A2280
Schmainda, 2014, Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma, Neuro Oncol, 16, 880, 10.1093/neuonc/not216
Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466
Kantoff, 2010, Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N Engl J Med, 363, 411, 10.1056/NEJMoa1001294
Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624
Camacho, 2009, Phase I/II trial of tremelimumab in patients with metastatic melanoma, J Clin Oncol, 27, 1075, 10.1200/JCO.2008.19.2435
Weber, 2008, Phase I/II study of ipilimumab for patients with metastatic melanoma, J Clin Oncol, 26, 5950, 10.1200/JCO.2008.16.1927
Okada, 2011, Do we need novel radiologic response criteria for brain tumor immunotherapy?, Expert Rev Neurother, 11, 619, 10.1586/ern.11.49
Floeth, 2002, Comparative follow-up of enhancement phenomena with MRI and proton MR spectroscopic imaging after intralesional immunotherapy in glioblastoma – report of two exceptional cases, Zentralbl Neurochir, 63, 23, 10.1055/s-2002-31579
Pollack, 2014, Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic–polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas, J Clin Oncol, 32, 2050, 10.1200/JCO.2013.54.0526